4/A: BridgeBio Pharma Director Increases Stake with Common Stock Purchase

BridgeBio Pharma, Inc. Director Hannah Valantine reported an acquisition of 1,752 shares of common stock at $14.24 per share, increasing her direct beneficial ownership.

Summary

• Hannah Valantine, a Director of BridgeBio Pharma, Inc. (BBIO), purchased 1,752 shares of common stock.
• The transaction occurred on December 29, 2021, at a price of $14.24 per share.
• Following this transaction, Hannah Valantine directly owns 3,294 shares of common stock.
• An additional 2,687 shares are indirectly beneficially owned by her spouse.
• This filing is an amendment (Form 4/A) to an original Form 4 filed on January 3, 2022.

Sentiment

Score: 7

Explanation: The purchase of shares by a director generally indicates confidence in the company's future performance, which is a positive signal for investors.

Positives

• A director, Hannah Valantine, purchased additional shares of common stock, signaling confidence in the company's future prospects.
• The purchase price of $14.24 per share indicates a specific valuation at which the insider chose to increase their stake.

Future Outlook

NA

Industry Context

This filing reflects an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The insider purchase may be viewed positively, potentially boosting investor confidence and share price.

Key Dates

Recommendation

Keywords

BridgeBio Pharma, BBIO, Insider Trading, Form 4/A, Stock Purchase, Director, Hannah Valantine, Beneficial Ownership, Equity Acquisition